Equity Profile

IMVT

Immunovant, Inc.

Health CareBiotechnology$8.6B

Aug10Mon

Pre-Earnings Brief

UpcomingQ1-2027Pre-Market9:00 AM EDT

Company Snapshot

Immunovant, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

-0.73

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Wall Street expectations, options signals, track record, and call prep available with Pro.

IMVT Q1-2027 Earnings Preview

Context

Company Snapshot

Immunovant, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases. With a market cap of $9 billion, it plays a significant role in the health care sector, particularly as demand for innovative treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.82%

Avg Stock Reaction

+4.85%

Last Quarter Recap

In Q4-2026, Immunovant reported an EPS of -0.73, missing the estimate of -0.60, which led to a significant stock increase of 35.26% the following day. This reaction suggests that investors may have been optimistic about future prospects despite the miss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Immunovant to report a loss of $0.73 per share this quarter, with no revenue anticipated. Investors will be closely watching for any signs of progress in product development or future revenue potential.

Bull Case

If Immunovant can beat EPS expectations and provide positive updates on its pipeline, it could lead to a significant rally in the stock, similar to past performance after earnings surprises.

Bear Case

A larger-than-expected loss or lack of clarity on future revenue could lead to a negative reaction, especially given the company's recent history of misses.

Key Metrics to Watch

EPS

-0.73

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of -0.73?

A surprise in EPS could significantly boost investor confidence and lead to a positive stock reaction.

What updates can be provided regarding the pipeline and future revenue potential?

Investors are eager to understand the company's growth trajectory, especially in light of the lack of expected revenue this quarter.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Immunovant to exceed EPS expectations given its recent history of surprises.

Supporting Evidence

The company has shown a tendency to surprise on the upside, with a 38% EPS beat rate historically.

Options pricing suggests a significant move, indicating that traders expect volatility and potential for a surprise.

Key Risk

If the company can provide a clearer outlook on its pipeline, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for Immunovant to turn around its recent performance and provide clarity on future revenue.

Bull Confirmed If

An EPS of -0.70 or better, along with positive commentary on the pipeline, would confirm the bull case.

Bear Confirmed If

An EPS worse than -0.76 would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±29.13%

Historical Avg

±9.6%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±29.1% while IMVT has averaged ±9.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

100.4%

Calls (69K)P/C Ratio: 0.06Puts (6K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunovant beats expectations, history suggests a potential average one-day move of +4.5%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with history suggesting an average one-day move of +5.06% when they miss.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of product development and timelines.
2Details on cost management strategies and their impact on EPS.
3Insights into market demand for Immunovant's therapies.
4Management's outlook on future revenue streams.
5Responses to analyst questions regarding competitive positioning.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

Immunovant, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

-0.73

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Wall Street expectations, options signals, track record, and call prep available with Pro.

IMVT Q1-2027 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.82%

Avg Stock Reaction

+4.85%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Immunovant can beat EPS expectations and provide positive updates on its pipeline, it could lead to a significant rally in the stock, similar to past performance after earnings surprises.

Bear Case

A larger-than-expected loss or lack of clarity on future revenue could lead to a negative reaction, especially given the company's recent history of misses.

Key Metrics to Watch

EPS

-0.73

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of -0.73?

A surprise in EPS could significantly boost investor confidence and lead to a positive stock reaction.

What updates can be provided regarding the pipeline and future revenue potential?

Investors are eager to understand the company's growth trajectory, especially in light of the lack of expected revenue this quarter.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Immunovant to exceed EPS expectations given its recent history of surprises.

Supporting Evidence

The company has shown a tendency to surprise on the upside, with a 38% EPS beat rate historically.

Options pricing suggests a significant move, indicating that traders expect volatility and potential for a surprise.

Key Risk

If the company can provide a clearer outlook on its pipeline, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for Immunovant to turn around its recent performance and provide clarity on future revenue.

Bull Confirmed If

An EPS of -0.70 or better, along with positive commentary on the pipeline, would confirm the bull case.

Bear Confirmed If

An EPS worse than -0.76 would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±29.13%

Historical Avg

±9.6%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±29.1% while IMVT has averaged ±9.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

100.4%

Calls (69K)P/C Ratio: 0.06Puts (6K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunovant beats expectations, history suggests a potential average one-day move of +4.5%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with history suggesting an average one-day move of +5.06% when they miss.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of product development and timelines.
2Details on cost management strategies and their impact on EPS.
3Insights into market demand for Immunovant's therapies.
4Management's outlook on future revenue streams.
5Responses to analyst questions regarding competitive positioning.